AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26571197 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-visitation program
Number of subjects: 704
Study 26571197 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 704
Study 24973026 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus an 8-week intervention (brief CBT delivered by trained frontline mental health staff)
Number of subjects: 66
Study 24973026 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 66
Study 22412067 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral artesunate
Number of subjects: 0
Study 22412067 — intervention group
Group type: COMPARATOR
Intervention: Parenteral quinine
Number of subjects: 0
Study 20810586 — intervention group
Group type: EXPERIMENTAL
Intervention: STIRR intervention
Number of subjects: 236
Study 20810586 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (control)
Number of subjects: 236
Study 17992478 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial variables (gender, depressiveness)
Number of subjects: 87
Study 17992478 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial variables (gender, age)
Number of subjects: 87
Study 15848600 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ARB therapy (started within 14 months after surgery)
Number of subjects: 52
Study 15848600 — intervention group
Group type: COMPARATOR
Intervention: Control group (never received ACEI/ARB)
Number of subjects: 52
Study 14624284 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg bid p.o.)
Number of subjects: 22
Study 14624284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 14624284 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 22
Study 10912979 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 mg (two doses)
Number of subjects: 142
Study 10912979 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two doses)
Number of subjects: 142
Study 10912979 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 142
Study 10912979 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 142
Study 9037790 — intervention group
Group type: EXPERIMENTAL
Intervention: Baxter reanimation formula (ringer lactated saline, RLS)
Number of subjects: 40
Study 9037790 — intervention group
Group type: COMPARATOR
Intervention: Monafo hypertonic lactated saline (HLS)
Number of subjects: 40
Study 1737254 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical pressure device (1.5 kPa warning)
Number of subjects: 102
Study 1737254 — intervention group
Group type: COMPARATOR
Intervention: No device (control group)
Number of subjects: 102
Study 1737254 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical pressure device
Number of subjects: 102
Study 6517812 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 300 I/ml
Number of subjects: 50
Study 6517812 — intervention group
Group type: COMPARATOR
Intervention: ioxaglate 320 mg I/ml
Number of subjects: 50
Study 3533315 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular moderate-intensity physical exercise (brisk walking to slow jogging)
Number of subjects: 0
Study 31851011 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise program (12-week duration, consisting of strengthening and stretching exercises)
Number of subjects: 32
Study 31851011 — intervention group
Group type: COMPARATOR
Intervention: Education-only control condition
Number of subjects: 32
Study 30025534 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (prescription review and league tables plus authorised feedback letter)
Number of subjects: 51
Study 30025534 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial intervention (prescription review and league tables)
Number of subjects: 51
Study 30025534 — intervention group
Group type: COMPARATOR
Intervention: Control (prescription review only)
Number of subjects: 51
Study 28632394 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate (LC) diet
Number of subjects: 102
Study 28632394 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Glycemic Load (RGL) diet
Number of subjects: 102
Study 28632394 — intervention group
Group type: COMPARATOR
Intervention: Standard Portion-Controlled (PC) diet
Number of subjects: 102
Study 26198306 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (SG)
Number of subjects: 64
Study 26198306 — intervention group
Group type: COMPARATOR
Intervention: Roux‐en‐Y gastric bypass (RYGB)
Number of subjects: 64
Study 23880495 — intervention group
Group type: EXPERIMENTAL
Intervention: Resourceful Adolescent Parent Program (RAP‐P) plus Routine Care (RC)
Number of subjects: 48
Study 23880495 — intervention group
Group type: COMPARATOR
Intervention: Routine Care (RC) only
Number of subjects: 48
Study 21912242 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial evaluation of ASA physical status grades
Number of subjects: 1554
Study 21912242 — intervention group
Group type: EXPERIMENTAL
Intervention: Final evaluation of ASA physical status grades
Number of subjects: 1554
Study 21912242 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement measurement
Number of subjects: 1554
Study 21912242 — intervention group
Group type: EXPERIMENTAL
Intervention: Underestimation of physical status
Number of subjects: 1554
Study 18190597 — intervention group
Group type: EXPERIMENTAL
Intervention: Western-style care sought by 858 (66.4%) of those with eye problems.
Number of subjects: 1470
Study 18190597 — intervention group
Group type: COMPARATOR
Intervention: Non-utilization of care associated with being illiterate (OR 3.7), rural dweller (OR 3.8), unemployed (OR 1.6), or farmer (OR 5.2).
Number of subjects: 1470
Study 18190597 — intervention group
Group type: COMPARATOR
Intervention: Lack of awareness of service availability (32.9%) was the most common reason for not seeking treatment.
Number of subjects: 1470
Study 18190597 — intervention group
Group type: COMPARATOR
Intervention: Attitudinal reasons (32.5%) were prevalent barriers to seeking care.
Number of subjects: 1470
Study 18190597 — intervention group
Group type: COMPARATOR
Intervention: Social (11.8%), economic (11.5%), and service-related (9.0%) issues were less prevalent barriers.
Number of subjects: 1470
Study 16507195 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope
Number of subjects: 56
Study 16507195 — intervention group
Group type: COMPARATOR
Intervention: Fibreoptic bronchoscope
Number of subjects: 56
Study 14500062 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation and atrial size reduction (n=24)
Number of subjects: 43
Study 14500062 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=19)
Number of subjects: 43
Study 10882447 — intervention group
Group type: EXPERIMENTAL
Intervention: Discoid lateral meniscus group
Number of subjects: 68
Study 10882447 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 68
Study 8768943 — intervention group
Group type: EXPERIMENTAL
Intervention: Aponeuron
Number of subjects: 20
Study 8768943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1579327 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG administration (2500 IU on days 3, 6, and 9 after ovulatory dose of 10,000 IU hCG)
Number of subjects: 67
Study 1579327 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment cycles (no luteal phase support)
Number of subjects: 67
Study 1579327 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG administration
Number of subjects: 67
Study 1579327 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment cycles
Number of subjects: 67
Study 3907322 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (360 mg/day, administered 2 times a day)
Number of subjects: 30
Study 3907322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31515555 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line maintenance capecitabine + bevacizumab
Number of subjects: 533
Study 31515555 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine + oxaliplatin + bevacizumab or another reintroduction treatment
Number of subjects: 533
Study 31515555 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutually adjusting models for BMI and SMI
Number of subjects: 533
Study 30099829 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of cortisol
Number of subjects: 24
Study 30099829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 27687362 — intervention group
Group type: EXPERIMENTAL
Intervention: 90° bend created by an intubating stylet (90D group, 35 patients)
Number of subjects: 70
Study 27687362 — intervention group
Group type: COMPARATOR
Intervention: Conventional insertion (C group, 35 patients)
Number of subjects: 70
Study 27687362 — intervention group
Group type: EXPERIMENTAL
Intervention: 90° bend created by an intubating stylet (90D group)
Number of subjects: 70
Study 27687362 — intervention group
Group type: COMPARATOR
Intervention: Conventional insertion (C group)
Number of subjects: 70
Study 24673497 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 633
Study 24673497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study 22961517 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (Tisseel(®)) applied to the donor-site chest wall
Number of subjects: 107
Study 22961517 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 107
Study 22961517 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (Tisseel(®))
Number of subjects: 107
Study 20525395 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence intervention (individual and group sessions, reminiscence boxes, posters, exhibitions)
Number of subjects: 0
Study 20525395 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence intervention
Number of subjects: 0
Study 20525395 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminiscence intervention)
Number of subjects: 0
Study 18332313 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole, 1%, eyedrops administered hourly for 4 doses
Number of subjects: 10
Study 18332313 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole, 1%, eyedrops administered every 6 hours for 3 days
Number of subjects: 10
Study 15973769 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment
Number of subjects: 201
Study 15973769 — intervention group
Group type: COMPARATOR
Intervention: Chronic hepatitis B patients without lamivudine treatment
Number of subjects: 201
Study 15071258 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OAC)
Number of subjects: 4052
Study 15071258 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA)
Number of subjects: 4052
Study 10204975 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal (39% energy as protein for men, 32% energy as protein for women)
Number of subjects: 0
Study 10204975 — intervention group
Group type: COMPARATOR
Intervention: Low-protein meal (5% energy as protein for women)
Number of subjects: 0
Study 10204975 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal
Number of subjects: 0
Study 7722207 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 0
Study 7722207 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal diet for postmenopausal women
Number of subjects: 0
Study 7722207 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term preventive measures
Number of subjects: 0
Study 7722207 — intervention group
Group type: EXPERIMENTAL
Intervention: WHI clinical trial and observational study
Number of subjects: 0
Study 1699989 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine (100 mg/day)
Number of subjects: 25
Study 1699989 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine (120 mg/day)
Number of subjects: 25
Study 1699989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1699989 — intervention group
Group type: COMPARATOR
Intervention: Normal Control (NC)
Number of subjects: 25
Study 632980 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous iron supplementation
Number of subjects: 0
Study 31605900 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial heating (SH)
Number of subjects: 22
Study 31605900 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam rolling (FR)
Number of subjects: 22
Study 31605900 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SH + FR
Number of subjects: 22
Study 31605900 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 29543077 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 Fr unipolar resectoscope (group A)
Number of subjects: 70
Study 29543077 — intervention group
Group type: COMPARATOR
Intervention: 26 Fr unipolar resectoscope (group B)
Number of subjects: 70
Study 27324577 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact-based antistigma presentation
Number of subjects: 198
Study 27324577 — intervention group
Group type: EXPERIMENTAL
Intervention: Education-based presentation
Number of subjects: 198
Study 27324577 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 198
Study 24164645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive oral hygiene regimen including dental prophylaxis at baseline and oral hygiene instructions at baseline, 4 and 8 weeks.
Number of subjects: 120
Study 22058209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-thalidomide-dexamethasone
Number of subjects: 1111
Study 22058209 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide-vincristine-doxorubicin-dexamethasone
Number of subjects: 1111
Study 19591604 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV risk reduction intervention
Number of subjects: 60
Study 19591604 — intervention group
Group type: COMPARATOR
Intervention: Health condition
Number of subjects: 60
Study 17613946 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized Employment Supports (CES) model
Number of subjects: 168
Study 17613946 — intervention group
Group type: COMPARATOR
Intervention: Standard vocational counseling (control)
Number of subjects: 168
Study 15377133 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminalia arjuna (500 mg q8h)
Number of subjects: 18
Study 15377133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11482921 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of abciximab and stenting as an adjunct to PTCA
Number of subjects: 0
Study 11482921 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding a stent to a procedure with abciximab
Number of subjects: 0
Study 11482921 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding abciximab to a stenting procedure
Number of subjects: 0
Study 11482921 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding abciximab in diabetic patients
Number of subjects: 0
Study 9683836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime + amikacin + teicoplanin (6 mg/kg once a day)
Number of subjects: 106
Study 9683836 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime + amikacin + vancomycin (30 mg/kg/day every 6 h)
Number of subjects: 106
Study 9683836 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (teicoplanin and vancomycin)
Number of subjects: 106
Study 7810811 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (25 mg/kg)
Number of subjects: 60
Study 7810811 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine (24 mg/kg or 72 mg/kg)
Number of subjects: 60
Study 7810811 — intervention group
Group type: EXPERIMENTAL
Intervention: Desbutyl-halofantrine
Number of subjects: 60
Study 7810811 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine
Number of subjects: 60
Study 3175849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary high-dose rate iridium irradiation
Number of subjects: 198
Study 3175849 — intervention group
Group type: COMPARATOR
Intervention: Intracavitary radium-226
Number of subjects: 198
Study 3175849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary high-dose rate iridium irradiation (younger patients)
Number of subjects: 198
Study 3175849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary high-dose rate iridium irradiation (older patients, 70 years and more)
Number of subjects: 198
Study 3175849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary high-dose rate iridium irradiation (tumor grading 1)
Number of subjects: 198
Study 3175849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary high-dose rate iridium irradiation (tumor grading 2 and 3)
Number of subjects: 198
Study 31953583 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive risk encouragement (e.g., 'You are cool if you continue')
Number of subjects: 356
Study 31953583 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative risk encouragement (e.g., 'You are a softy if you do not continue')
Number of subjects: 356
Study 31953583 — intervention group
Group type: COMPARATOR
Intervention: Solo (no peers)
Number of subjects: 356
Study 28688742 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 50mg/day plus clozapine 100mg/day
Number of subjects: 85
Study 28688742 — intervention group
Group type: COMPARATOR
Intervention: Clozapine 300mg/day (monotherapy)
Number of subjects: 85
Study 27154970 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentivized smoking cessation program
Number of subjects: 74
Study 27154970 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referrals from media
Number of subjects: 74
Study 27154970 — intervention group
Group type: EXPERIMENTAL
Intervention: Referrals from cessation providers
Number of subjects: 74
Study 27154970 — intervention group
Group type: EXPERIMENTAL
Intervention: Referrals from health professionals
Number of subjects: 74
Study 27154970 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with participants
Number of subjects: 74
Study 24773572 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training program
Number of subjects: 265
Study 24773572 — intervention group
Group type: COMPARATOR
Intervention: Health promotion training program
Number of subjects: 265
Study 22799601 — intervention group
Group type: EXPERIMENTAL
Intervention: home‐based integrated rehabilitation program (progressive resistance strength training, movement strategy training and falls education)
Number of subjects: 180
Study 22799601 — intervention group
Group type: COMPARATOR
Intervention: home‐based life skills program (control intervention)
Number of subjects: 180
Study 22799601 — intervention group
Group type: EXPERIMENTAL
Intervention: home‐based integrated rehabilitation program
Number of subjects: 180
Study 19853334 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cruciate ligament substituting design
Number of subjects: 18
Study 19853334 — intervention group
Group type: COMPARATOR
Intervention: Traditional curved symmetric articular configuration
Number of subjects: 18
Study 18076247 — intervention group
Group type: EXPERIMENTAL
Intervention: Short rest between sets (1 minute; SR)
Number of subjects: 21
Study 18076247 — intervention group
Group type: EXPERIMENTAL
Intervention: Long rest between sets (4 minutes; LR)
Number of subjects: 21
Study 18076247 — intervention group
Group type: COMPARATOR
Intervention: Nontraining control group (CG)
Number of subjects: 21
Study 16110222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural group psychotherapy (20 sessions over 20 weeks)
Number of subjects: 73
Study 16110222 — intervention group
Group type: COMPARATOR
Intervention: Routine MMT (control group)
Number of subjects: 73
Study 12099322 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid fixation of the maxilla (RMF)
Number of subjects: 42
Study 12099322 — intervention group
Group type: COMPARATOR
Intervention: Semirigid fixation of the maxilla (SRMF)
Number of subjects: 42
Study 8723572 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 600 IU/kg administered intravenously twice weekly for 3 weeks (in conjunction with oral iron supplementation)
Number of subjects: 0
Study 8723572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1691132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic alternating drugs (DNR + VCR + Ara-C)
Number of subjects: 515
Study 1691132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 515
Study 508556 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg three times daily dipyridamole + 180 mg ASA
Number of subjects: 0
Study 508556 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg three times daily dipyridamole + 120 mg ASA daily
Number of subjects: 0
Study 508556 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg dipyridamole three times daily + 60 mg ASA
Number of subjects: 0
Study 508556 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of dipyridamole and ASA
Number of subjects: 0
Study 508556 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of ASA in combination with dipyridamole
Number of subjects: 0
Study 30183431 — intervention group
Group type: EXPERIMENTAL
Intervention: Allied health intervention prioritised for low functioning and complex patients
Number of subjects: 25
Study 30183431 — intervention group
Group type: COMPARATOR
Intervention: Current practice prioritising discharge
Number of subjects: 25
Study 31542747 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation in conjunction with resistance training
Number of subjects: 0
Study 31542747 — intervention group
Group type: COMPARATOR
Intervention: Placebo in conjunction with resistance training
Number of subjects: 0
Study 27989693 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of artificial tear containing dextran 70 (1mg/ml) and hypromellose (3mg/ml)
Number of subjects: 88
Study 27989693 — intervention group
Group type: COMPARATOR
Intervention: Multidose of artificial tear containing 0.3g HPMC and 0.1g of dextran 70 with 0.01% benzalkonium chloride (BAK) as preservative
Number of subjects: 88
Study 27989693 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Group A and Group B)
Number of subjects: 88
Study 28682277 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate jet prophylaxis
Number of subjects: 40
Study 28682277 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive)
Number of subjects: 40
Study 28682277 — intervention group
Group type: COMPARATOR
Intervention: Control group (hypertensive)
Number of subjects: 40